News Breaks |
|
|
| February 5, 2013 |
| 10:50 EDT |  | YMI, GILD | YM Biosciences says Supreme Court of Nova Scotia approves deal
YM BioSciences (YMI) announced that the Supreme Court of Nova Scotia has issued a final order approving the previously announced plan of arrangement involving the company and Gilead (GILD). Under the arrangement, Gilead will acquire all of the issued and outstanding common shares of YM Biosciences for cash consideration of $2.95 per share. Assuming all other closing conditions are satisfied or waived, it is anticipated that the arrangement will become effective on February 8. |
|
|
News For YMI;GILD From The Last 14 Days Check below for free stories on YMI;GILD the last two weeks. |
|
|
| June 18, 2013 |
| 07:28 EDT |  | GILD | Wells Faro to host a conference
 Subscribe for More Information |
|
| June 17, 2013 |
| 16:00 EDT |  | GILD | Options Update; June 17, 2013
Subscribe for More Information |
|
| 06:25 EDT | | GILD | Gilead reports interim Phase 2 data for Idelalisib
Gilead announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy. Previously, this has been a largely unstudied population for which there is significant unmet medical need for effective therapy. In the study, single-agent treatment with idelalisib achieved an overall response rate of 53.6%, with a median duration of response at this interim analysis of 11.9 months. The most common Grade ≥3 adverse event was diarrhea . Grade ≥3 transaminase elevations were reported via central laboratory testing in 13% of patients; Grade ≥3 neutropenia occurred in 26% of patients. Sixteen percent of patients discontinued due to adverse events. |
|
| June 13, 2013 |
| 10:05 EDT |  | GILD | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 07:33 EDT | | GILD | Gilead upgraded to Buy from Hold at Argus
Subscribe for More Information |
|
| June 10, 2013 |
| 07:40 EDT | | GILD | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information |
|
| June 7, 2013 |
| 17:21 EDT | | GILD | Gilead announces U.S. FDA priority review designation for Sofosbuvir
Subscribe for More Information |
|
| June 6, 2013 |
| 09:07 EDT |  | GILD | Gilead Sofosbuvir likely to be granted priority review, says RBC Capital
Subscribe for More Information |
|
| 08:27 EDT | | GILD | Bernstein's biotech analysts hold an analyst/industry conference call
Subscribe for More Information |
|
|
|
|
|
